Gracell Biotechnologies Inc. - Asset Resilience Ratio
Gracell Biotechnologies Inc. (GRCL) has an Asset Resilience Ratio of 1.61% as of September 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Gracell Biotechnologies Inc. total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2022)
This chart shows how Gracell Biotechnologies Inc.'s Asset Resilience Ratio has changed over time. See GRCL total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Gracell Biotechnologies Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Gracell Biotechnologies Inc..
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $30.46 Million | 1.61% |
| Total Liquid Assets | $30.46 Million | 1.61% |
Asset Resilience Insights
- Limited Liquidity: Gracell Biotechnologies Inc. maintains only 1.61% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Gracell Biotechnologies Inc. Industry Peers by Asset Resilience Ratio
Compare Gracell Biotechnologies Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sagimet Biosciences Inc. Series A Common Stock
NASDAQ:SGMT |
Biotechnology | 63.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
Inner Mongolia Furui Med Sci
SHE:300049 |
Biotechnology | 2.34% |
|
Bio-Thera Solutions Ltd
SHG:688177 |
Biotechnology | 4.09% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Gubra A/S
CO:GUBRA |
Biotechnology | 79.61% |
Annual Asset Resilience Ratio for Gracell Biotechnologies Inc. (2018–2022)
The table below shows the annual Asset Resilience Ratio data for Gracell Biotechnologies Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 0.21% | $3.56 Million | $1.66 Billion | +0.04pp |
| 2021-12-31 | 0.18% | $3.62 Million | $2.06 Billion | -1.77pp |
| 2020-12-31 | 1.94% | $18.74 Million | $964.95 Million | +0.92pp |
| 2019-12-31 | 1.02% | $4.20 Million | $412.22 Million | -67.66pp |
| 2018-12-31 | 68.68% | $102.00 Million | $148.52 Million | -- |
About Gracell Biotechnologies Inc.
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enable… Read more